Biolexis Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In American Forkutahfounded In 2021The Company Is Dedicated To Accelerating Human Longevity By Developing Oral Small Molecule Therapeutics Aimed At Chronic Diseasesincluding Metabolic Disorderscancersneurodegenerative Conditionsand Autoimmune Diseasesbiolexis Focuses On Addressing Age Related Diseases Through Innovative Metabolic And Anti Inflammatory Solutions The Company Utilizes Proprietary Platforms Such As Moleculerna Cwhich Enhances Drug Discovery By Rapidly Identifying And Optimizing Clinical Candidatesand Fieldswhich Identifies Protein Targets Driving Disease Pathologybiolexis Is Actively Working On Therapies For Obesitydiabetesneurodegenerative Diseasescancerand Autoimmune Conditionswith Recent Positive Results From Expanded Clinical Trialsthe Leadership Team Includes Co Founders Drdavid Bearss And Drhariprasad Vankayalapatiwho Bring Extensive Experience In Drug Development And Targeted Therapeuticsbiolexis Aims To Improve The Quality Of Life For Aging Populations While Addressing The Economic Impact Of Chronic Disease Management
